Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy by Carina Wattmo et al.
RESEARCH Open Access
Mild versus moderate stages of Alzheimer's
disease: three-year outcomes in a routine
clinical setting of cholinesterase inhibitor
therapy
Carina Wattmo*, Lennart Minthon and Åsa K. Wallin
Abstract
Background: There is an increasing interest in cognitive and functional outcomes in the respective stages of
Alzheimer’s disease (AD) and in novel therapies particularly for the milder phases of AD. Our aim was to describe
and compare various aspects of disease progression in patients with mild versus moderate AD in routine clinical
practice of cholinesterase inhibitor (ChEI) therapy.
Methods: This 3-year, prospective, observational, multicentre study included 1021 participants. Of these, 734 had
mild AD (Mini-Mental State Examination (MMSE) score, 20–26) and 287 had moderate AD (MMSE score, 10–19)
at the start of ChEI treatment. At baseline and every 6 months, patients were assessed using cognitive, global,
instrumental and basic activities of daily living (ADL) scales. Potential predictors of deterioration in moderate AD
were analysed using mixed-effects models.
Results: The change from baseline between participants with mild and moderate stages of AD after 3 years of ChEI
therapy differed significantly on the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and basic
ADL, but not using the MMSE and instrumental ADL scales. Protective independent factors for better cognitive
long-term outcome in the group with moderate AD were older age, higher instrumental ADL ability, no antipsychotics,
usage of non-steroidal anti-inflammatory drugs/acetylsalicylic acid, living with family member, lower education and
a higher mean dose of ChEI. Apolipoprotein E genotype did not influence the rates of disease progression or the
longitudinal outcomes. Prediction models were provided for moderate AD.
Conclusions: More sensitive cognitive measures, such as the ADAS-cog scale, are required to detect a possibly faster
deterioration among the participants with moderate AD. This study highlighted the clinical importance of instrumental
ADL evaluations in patients at a mild stage of AD, and the importance of optimizing the ChEI dose even for individuals
with moderate AD. Solitary living was a risk factor for faster cognitive decline, and probably expanded the need for
formal care in the group with moderate AD. The patients with more advanced AD and presumably more pronounced
neuroinflammation might have additional cognitive benefits from longer-term treatment with anti-inflammatory drugs.
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Background
The course of Alzheimer’s disease (AD) may be de-
scribed in different stages because these patients exhibit
different symptoms over time. However, the clinical
presentation of AD and the progression of symptoms
might show considerable heterogeneity among the affected
individuals. In general, AD starts with mild impairments
in memory, communication patterns and executive ability,
and depression, which can be an early symptom of AD [1].
A marked reduction in the capacity to conduct more
advanced instrumental activities of daily living (ADL) has
also been observed in persons with mild AD [2]. Common
symptoms in the moderate stage are disorientation of
time and/or place, dyspraxia, dysgnosia and decreased
judgement and skills with regard to basic ADL. Moreover,
when the disease progresses, it is often accompanied by
social withdrawal, changes in behaviour and psychotic
symptoms [1].
Cholinesterase inhibitors (ChEIs) are the main recom-
mended symptomatic treatment for patients with mild
to moderate AD, and they are understood to work by
increasing the level of acetylcholine in the neuronal
synaptic clefts in the brain [3]. The level of short-term
therapeutic response and longitudinal outcome may vary
among those at the various stages of AD. Several studies
have reported a better 6-month cognitive response to
all three ChEIs for individuals in the moderate to
moderate/severe stages [4–6], while long-term benefits
of ChEI treatment were more pronounced in those
patients with milder AD [7].
There is an increased interest in cognitive and functional
outcomes according to the stages of AD, and in new ther-
apies aimed at blocking the course of the disease especially
in the early stages. The medical food Souvenaid (Nutricia
N.V., Zoetermeer, The Netherlands) showed significant
cognitive improvement compared with placebo in partici-
pants with mild AD exclusively, but failed in a cohort of pa-
tients with both mild and moderate AD [8]. Passive
immunization with the anti-beta-amyloid antibody solane-
zumab yielded small but significant positive cognitive
effects in individuals with mild AD [9]; however, the
final phase 3 analyses observed no treatment–placebo
differences in participants with either mild or moderate
AD [10]. A phase 2 trial of idalopirdine + donepezil re-
ported a significant improvement in cognitive ability in
patients with moderate AD compared with donepezil
therapy alone [11]. New longer studies are usually add-on
studies – that is, performed using participants who are
already being treated with ChEIs – because placebo-
controlled trials lasting longer than 6 months in individ-
uals with untreated AD are not permitted for ethical rea-
sons. Knowledge of the longitudinal cognitive and
functional outcomes in different stages of AD are of great
importance for the evaluation of future add-on therapies
(e.g. calculation of adequate sample sizes). New therapies
that might modify AD progression require thorough
assessment over several years; hence, the rates of change
in well-designed observational studies can be used for
comparisons.
Few earlier long-term studies focused on reporting
data for ChEI-treated participants in the mild and moder-
ate AD stages. Moreover, to our knowledge, no compara-
tive studies of different aspects of disease progression in
these stages over longer times have been reported. An ob-
servational study of the cognitive and ADL outcomes over
3 years of ChEI therapy of mild AD was described by our
group [2]; the Alzheimer’s Disease Neuroimaging Initiative
presented the 2-year cognitive decline in ChEI-treated
patients in the mild stage of AD [12]; and an 18-month
randomized controlled trial of tarenflurbil exclusively in
participants with mild AD showed rates of change in cog-
nition over time for the ChEI-treated and/or memantine-
treated ‘placebo’ group [13]. No longitudinal studies have
previously reported the progression in different domains
or possible predictors that might affect the disease course
in a cohort with exclusively moderate AD.
The present study aimed to compare various long-
term outcomes between patients with mild or moderate
AD in a routine clinical setting of ChEI therapy, and
aimed to describe and predict cognitive, global and
functional longitudinal progression in individuals with
moderate AD. Disease progression regarding the group
with mild AD was published previously [2].
Methods
Study and participants
The Swedish Alzheimer Treatment Study (SATS) is a 3-
year, prospective, open, non-randomized multicentre study
with the purpose of assessing long-term ChEI treatment
(donepezil, rivastigmine and galantamine) in routine clin-
ical practice. Several publications have previously reported
various findings from the SATS [2, 6, 7, 14]. In total, 1258
participants with AD were recruited from 14 memory
clinics in different areas of Sweden. Of these, 734 individ-
uals were defined as having mild AD (Mini-Mental State
Examination (MMSE) [15] score, 20–26) and 287
individuals as having moderate AD (MMSE score,
10–19) at the start of ChEI therapy (baseline) and
were included in the present study.
The inclusion criteria were outpatients aged 40 years
and older who received a clinical diagnosis of dementia as
defined by the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) [16] and pos-
sible or probable AD according to the criteria of the
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) [17]. In
addition, the participants were required to be community
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dwelling with or without home-help services at the time of
AD diagnosis, to have a responsible caregiver and to be
capable of being evaluated using the MMSE scale at the ini-
tiation of ChEI treatment. Exclusion criteria were not fulfill-
ing the diagnostic criteria for AD, already receiving active
ChEI therapy or contraindications to ChEI. Concomitant
medications other than ChEIs were recorded at baseline
and allowed during the study, except for memantine.
If memantine therapy was commenced, the individual
dropped out from the SATS at that time point.
The SATS participants were investigated in a struc-
tured, follow-up programme over 3 years that investi-
gated cognition, global performance and instrumental
and basic ADL abilities, at the start of ChEI treatment,
after 2 months (MMSE and global rating only) and every
6 months. Nurses trained to care for patients with de-
mentia assessed the ADL capacity based on interviews
with the caregiver. The dates of eventual nursing home
placement and death were documented, as well as the
date of, and reason for, any withdrawal from the SATS.
After inclusion in the study and the baseline evaluations,
the participants were prescribed ChEI therapy as part of
the ordinary Swedish health care system, in accordance
with the approved product labelling. The SATS is an obser-
vational study and the choice of ChEI agent and dose was
left entirely up to the dementia specialist’s discretion and
professional judgement. The ChEI dose was recorded after
2 months of treatment and then semi-annually after base-
line. If the patient stopped taking the ChEI, the individ-
ual was excluded from the study at that time point.
Ethics, consent and permissions
All patients and/or their caregivers gave their written
informed consent to participate in the SATS, which was
conducted according to the provisions of the Helsinki
Declaration and was approved by the Ethics Committee
of Lund University, Sweden.
Outcome measures
Cognitive status was assessed using the MMSE scale (with
scores ranging from 0 to 30; a lower score indicates more
impaired cognition) and the Alzheimer’s Disease Assess-
ment Scale—cognitive subscale (ADAS-cog) [18] (0–70
points; a lower score indicates higher cognitive ability).
The Clinician Interview-Based Impression of Change
(CIBIC) [19] was used as a global rating of ‘change from
the start of ChEI treatment’. The evaluations were per-
formed at all intervals using a 7-point scale that varied
from 1 (very much improved) to 7 (marked worsening).
Three groups of response were defined at each CIBIC
interval: 1–3 indicated improvement, 4 indicated no
change and 5–7 indicated worsening. No guidelines
or descriptors were provided to define the individual
ratings. The classification between, for example, minimally
improved or very much improved was left to the dementia
specialist’s clinical judgement.
The functional capacity was assessed using the
Instrumental Activities of Daily Living (IADL) scale
[20], which comprises eight items: ability to use the
telephone, shopping, food preparation, housekeeping, abil-
ity to do laundry, mode of transportation, responsibility for
own medications and ability to handle finances. Each item
was scored from 1 (no impairment) to 3–5 (severe impair-
ment), thus allowing a total range of 8–31 points. Basic
ADL was measured by the Physical Self-Maintenance Scale
(PSMS) [20] comprising six items: toilet, feeding, dressing,
grooming, physical ambulation and bathing. Each item
was scored from 1 (no impairment) to 5 (severe impair-
ment), thus allowing a total range of 6–30 points.
For each follow-up visit, we calculated the mean
MMSE, ADAS-cog, IADL and PSMS changes from
baseline with 95 % confidence intervals (CI). To facilitate
comparisons of these rates, we converted the change in
score to positive values (indicating improvement) and
negative values (indicating worsening). The proportions
of improved/unchanged SATS patients, predefined as
those who demonstrated an improvement or no change
(≥0 points difference) at the respective evaluation, were
also calculated for the MMSE, ADAS-cog, IADL and
PSMS scales.
Nursing home placement was defined as the permanent
admission to a licensed skilled nursing facility with 24-hour
care; that is, rehabilitative or respite care was not included.
If hospitalization occurred before nursing home entry, the
date of hospital admission was used. Using the 12-digit
personal identity number assigned to each resident of
Sweden, we determined whether each participant in the
study was still alive on 31 December 2013 with the help of
the Swedish population register (Swedish Tax Agency). If
not, the date of death was recorded.
Statistical analyses
The IBM Statistical Package for the Social Sciences
(SPSS) for Windows (version 22.0; IBM Corporation,
Armonk, NY, USA) was used to perform the statistical
analyses. The level of significance was defined as p <0.05,
unless otherwise specified, and all tests were two-tailed.
Observed-case analyses were used to avoid overestimation
of the therapeutic effect by imputing earlier, better outcome
scores in a long-term study of a progressively deteriorating
disease. Parametric tests were used because of the large
sample size and the approximately normally distributed
continuous potential predictors. Independent-sample t tests
were used to compare the differences between the means
for two groups, and chi-square tests were conducted to
analyse categorical variables. Pearson’s correlation coeffi-
cient was calculated to investigate any linear associations
between continuous variables.
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Mixed, linear and non-linear fixed and random coeffi-
cient regression models using the subject as a hierarch-
ical variable (to consider the intra-individual correlation)
were performed. In addition, the mixed-effects models
took into account the varying number of assessments
available for each patient and unequal time intervals
between follow-ups, which are the usual concerns in
longitudinal studies. The individuals who discontinued
the study contributed information during their time
of participation; hence, we considered the trajectories
of all patients in the SATS.
Time was defined as the exact number of months be-
tween the start of ChEI therapy and each visit, which
implies that all data points were used at the actual time
intervals. To adjust for baseline differences, the initial
cognitive, instrumental or basic ADL scores for each in-
dividual and their interaction with linear and quadratic
terms for time in the study (to enable a non-linear rate
of change in the models) were included as fixed effects;
that is, time in months (and time in months2) ×MMSE
(ADAS-cog, IADL or PSMS) baseline score. Thus, the
dependent variables were the cognitive or functional
scores assigned at the second and subsequent evalua-
tions for each participant; the mixed-effects models do
not intend to predict the scores at the initiation of ChEI
treatment. The random terms were an intercept and
time in months, with a variance components covariance
matrix. Several potential socio-demographic and clinical
predictors were included as fixed effects in the models,
such as sex, age at the start of ChEI therapy, clinician’s
estimate of age at AD onset, years of education, presence
of the apolipoprotein E (APOE) ε4 allele (no/yes), soli-
tary living (no/yes), number of medications at baseline,
and specific concomitant medications (no/yes for each
group) including antihypertensive/cardiac therapy, antidia-
betics, asthma medication, thyroid therapy, lipid-lowering
agents, oestrogens, non-steroidal anti-inflammatory drugs
(NSAIDs)/acetylsalicylic acid, antidepressants, antipsy-
chotics and anxiolytics/sedatives/hypnotics. The effect
of ChEIs was analysed using the drug agents (coded
as a set of dummy variables) and dosages. The ChEI
dose could vary during the treatment period for an
individual patient and between patients; therefore, the
mean dose used during the entire follow-up period was
calculated for each participant. In cases of drop-out, the
mean dose used during the individual’s time of participa-
tion in the SATS was calculated. To obtain a similar metric
for percentage maximum dosage for each of the three
ChEIs, the mean dose was divided by the maximum rec-
ommended dose for each drug; that is, 10 mg for donepe-
zil, 12 mg for rivastigmine (oral administration) and 24 mg
for galantamine. The term ‘ChEI agent × dose’ was also
included in the models. Furthermore, some potential inter-
actions (gender, age or education) with disease severity at
baseline or with time in the study were included in the
models. Non-significant variables (p >0.05) were eliminated
in a backward stepwise manner. The hierarchical principle
was applied in the mixed-effects models; variables
that appeared in significant interactions were not con-
sidered for elimination.
Results
Socio-demographic and clinical characteristics according
to stage of AD
The 1021 SATS participants were divided into two
groups according to their cognitive status at the start of
ChEI therapy (baseline): mild AD (MMSE score, 20–26;
n = 734 (72 %)) and moderate AD (MMSE score, 10–19;
n = 287 (28 %)). The socio-demographic and clinical
characteristics of the two groups are presented in
Table 1. In the mild cohort, the proportion of anti-
psychotic medications was lower (χ2(1) = 6.69; p = 0.013).
The patients with mild AD also had significantly more
years of education, on average, compared with those in
the moderate group (t(1017) = 3.82; p <0.001).
The 3-year completion rate was higher (χ2(1) = 15.98;
p <0.001) and the mean time of participation in the
study was longer (t(1019) = 4.24; p <0.001) for the cohort
with mild AD compared with moderate AD. A higher
percentage of individuals with moderate AD received
donepezil and a lower percentage rivastigmine compared
with those in the group with mild AD (χ2(2) = 6.70;
p = 0.035). No differences in sex, APOE genotype, age at
onset or at baseline, ChEI dose or use of other medica-
tions at baseline were detected between the two groups.
Comparisons of longitudinal outcomes between mild and
moderate AD
The mean MMSE, ADAS-cog, IADL and PSMS changes
from baseline scores during 3 years for the SATS patients
with mild and moderate AD are shown in Fig. 1a–d. After
3 years of ChEI treatment, the mean decline (95 % CI)
from baseline for mild and moderate AD was: MMSE
score, 3.1 (2.5–3.7) vs. 4.0 (2.8–5.2) points (t(368) = 1.45;
p = 0.148); ADAS-cog score, 6.1 (4.9–7.4) vs. 13.2
(10.3–16.2) points (t(329) = 4.84; p <0.001); IADL score, 6.3
(5.7–6.9) vs. 7.5 (6.3–8.7) points (t(354) = 1.87; p = 0.063);
and PSMS score, 2.3 (2.0–2.7) vs. 4.9 (3.9–5.8) points
(t(355) = 4.82; p <0.001). The changes in global perform-
ance (CIBIC) from the initiation of ChEIs and over the 3-
year study are shown in Fig. 2a. After 1 year of therapy,
global improvement or no change was observed in 61 %
of the remaining mild cohort vs. 41 % of the remaining
moderate cohort (χ2(1) = 23.75; p <0.001); after 2 years,
43 % vs. 27 % (χ2(1) = 10.37; p = 0.001); and after 3 years,
33 % vs. 15 % of the remaining individuals were im-
proved/unchanged (χ2(1) = 9.15; p = 0.002). No significant
linear associations were found between cognitive, IADL or
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basic ADL abilities at the baseline, or their rates of change
during the study, and the mean dose of ChEI.
The participants with mild and moderate AD, re-
spectively, were further divided into APOE genotypes.
No significant difference in ADAS-cog or PSMS change
after 3 years of ChEI treatment was observed between
the mild non-carriers and carriers of the ε4 allele, or
between the moderate non-carriers and carriers of the
ε4 allele. No difference in change from baseline after
3 years was found in MMSE and IADL scores between
the four groups. The proportion of globally improved/
unchanged patients was not different between non-
carriers and carriers of the ε4 allele either with mild
AD or moderate AD.
End-points in mild vs. moderate AD
Overall, 428 participants (58 %) with mild AD and 209
participants (73 %) with moderate AD did not complete
the 3-year study (χ2(1) = 15.98; p <0.001). The reasons
for drop-out are shown in Fig. 2b. Initiation of meman-
tine therapy (χ2(1) = 20.26; p <0.001) and poor effect/
deterioration (χ2(1) = 11.33; p = 0.002) were more fre-
quent reasons in the cohort with moderate AD, while
switching to another study (χ2(1) = 6.47; p = 0.010) was
more common among patients with mild AD. Thirty-
eight (5 %) of the individuals with mild AD and 11 indi-
viduals (4 %) with moderate AD dropped out of the
study because of compliance problems (χ2(1) = 0.82;
p = 0.419).
Table 1 Socio-demographic and clinical characteristics (n = 1021)
Variable Mild AD
(n = 734, 72 %)
Moderate AD
(n = 287, 28 %)
p
Female sex 473/64 % 181/63 % 0.717
APOE ε4 carrier, (n = 999) 493/69 % 186/66 % 0.452
Solitary living at baseline 267/36 % 88/31 % 0.093
Completion rate after 3 years 306/42 % 78/27 % <0.001
Antihypertensives/cardiac therapy 290/40 % 124/43 % 0.288
Antidiabetics 38/5 % 12/4 % 0.629
Asthma medication 28/4 % 16/6 % 0.231
Thyroid therapy 65/9 % 20/7 % 0.378
Lipid-lowering agents 94/13 % 24/8 % 0.050
Oestrogens 52/7 % 17/6 % 0.580
NSAIDs/acetylsalicylic acid 221/30 % 84/29 % 0.820
Antidepressants 183/25 % 74/26 % 0.810
Antipsychotics 26/4 % 21/7 % 0.013
Anxiolytics/sedatives/hypnotics 111/15 % 37/13 % 0.429
Estimated age at onset (years) 72.3 ± 7.1 72.0 ± 7.8 0.544
Estimated duration of AD at baseline (years) 2.9 ± 2.0 3.4 ± 2.3 0.005
Age at first assessment (years) 75.2 ± 6.8 75.3 ± 7.4 0.788
Education (years) 9.6 ± 2.6 9.0 ± 2.2 <0.001
MMSE score at baseline 23.4 ± 2.0 16.4 ± 2.2 <0.001
ADAS-cog score (0–70) at baseline 17.5 ± 6.7 29.3 ± 8.3 <0.001
IADL score at baseline 14.7 ± 5.0 19.1 ± 5.1 <0.001
PSMS score at baseline 7.2 ± 1.9 8.3 ± 2.9 <0.001
Number of concomitant medications at baseline 2.9 ± 2.4 3.0 ± 2.6 0.604
Length in the SATS (months) 24.2 ± 12.9 20.4 ± 13.0 <0.001
Mean dose of ChEI during the follow-up period (mg)
Donepezil (n = 518)a 6.9 ± 1.7 (48 %) 6.9 ± 1.8 (57 %) 0.761
Rivastigmine (n = 212)a 6.2 ± 2.1 (22 %) 6.0 ± 2.2 (17.5 %) 0.536
Galantamine (n = 291)a 15.3 ± 3.6 (30 %) 14.7 ± 4.0 (25.5 %) 0.198
Data presented as n/% or mean ± standard deviation
aPercentage of patients in each group that received the specific ChEI agent in parentheses (chi-square test; p = 0.035)
AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale—cognitive subscale, APOE apolipoprotein E, ChEI cholinesterase inhibitor, IADL Instrumental
Activities of Daily Living scale, MMSE Mini-Mental State Examination, NSAID non-steroidal anti-inflammatory drug, PSMS Physical Self-Maintenance Scale, SATS Swedish
Alzheimer Treatment Study
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During the SATS, 141 participants (19 %) with mild
AD and 91 participants (32 %) with moderate AD
(χ2(1) = 18.35; p <0.001) were admitted to nursing
homes. Figure 3a presents the Kaplan–Meier graph
for the distribution of time from baseline to nursing home
placement for the mild and moderate groups (log–rank
test, p <0.001). However, the mean time (95 % CI) from the
start of ChEI treatment to institutionalization was similar
for patients with mild and moderate AD (20.0 (18.4–21.6)
months vs. 19.0 (16.8–21.1) months; p = 0.449).
After the 3-year study, 88 individuals (12 %) with
mild AD and 47 individuals (16 %) with moderate
AD had died (p = 0.065), and after up to 16 years of
follow-up 578 individuals (79 %) and 263 individuals
(92 %) (χ2(1) = 23.61; p <0.001), respectively, had died.
Figure 3b presents the Kaplan–Meier graph for the distri-
bution of time from the initiation of ChEI therapy to death
for patients with mild and moderate AD (log–rank test,
p <0.001). The mean survival time from the baseline
was 6.2 (5.9–6.4) years and 5.5 (5.2–5.8) years (t(839) = 3.34;
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Fig. 1 Cognitive and functional outcomes over 3 years of ChEI treatment. a Mean changes in MMSE score with 95 % CI from the start of ChEI
therapy over 3 years according to the stage of AD. The SATS patients with moderate AD exhibited a better short-term cognitive outcome after
2 months (p <0.001) and 6 months (p = 0.003) of therapy. No significant difference was found between the two disease stages at the other evaluations.
b Mean changes in ADAS-cog score with 95 % CI from the start of ChEI therapy over 3 years according to the stage of AD. The patients with mild AD
showed a more positive longitudinal cognitive outcome from the 12-month assessment (p <0.001). c Mean changes in IADL score with 95 % CI from
the start of ChEI therapy over 3 years according to the stage of AD. The patients with mild AD exhibited a better functional outcome after 12 months
(p = 0.021). No significant difference was detected between the two disease stages at the other evaluations. d Mean changes in PSMS
score with 95 % CI from the start of ChEI therapy over 3 years according to the stage of AD. The patients with mild AD showed a more
favourable long-term outcome in basic ADL from the 6-month assessment (p <0.001). AD Alzheimer’s disease, ADAS-cog Alzheimer’s
Disease Assessment Scale—cognitive subscale, CI confidence interval, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental
State Examination, PSMS Physical Self-Maintenance Scale
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p = 0.001) for individuals with mild and moderate AD,
respectively.
Longitudinal outcomes and prediction models in
moderate AD
The mean MMSE, ADAS-cog, IADL and PSMS actual
scores and the changes from baseline scores during
3 years are presented in Table 2. The proportions of par-
ticipants with moderate AD who exhibited improvement
or remained unchanged at each visit according to
these measures are also reported. The aforementioned
outcomes for the patients with mild AD in the SATS
have been published previously [2].
To enable analyses of a non-linear rate of cognitive or
functional change in the mixed-effects models, only indi-
viduals with three or more assessments (n = 249, 86.8 %)
were included. The models were studied (1129 data
points) to identify the socio-demographic and clinical
variables that affected the long-term trajectories of pa-
tients with moderate AD. The percentages of variance
that accounted for the dependent variable, regarding all
























































Improvement Unchanged Deterioration Drop-out
   Moderate



















CIBIC, changes in global performance
Reasons for drop-out
Mild AD Moderate AD
Fig. 2 Proportion of SATS participants. a Proportion of patients according to differences in treatment response in global performance (CIBIC) from
the start of ChEI therapy over 3 years for mild vs. moderate AD (***p <0.001, **0.001≤ p <0.01, *p <0.05). CIBIC score 1–3 was considered as improvement,
4 as unchanged and 5–7 as deterioration. b Proportion of patients who discontinued the study for various reasons according to the stage of their AD.
Initiation of memantine therapy (p <0.001) and poor effect/deterioration (p = 0.002) were more frequent reasons for drop-out in the cohort with moderate
AD; switching to another study (p = 0.010) was more common among the patients with mild AD. No significant difference between the disease stages
was observed for the other reasons for drop-out. AD Alzheimer’s disease, ChEI cholinesterase inhibitor, CIBIC Clinician Interview-Based Impression of Change
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ADAS-cog, 56.0 % for IADL and 39.9 % for PSMS, indi-
cating a good fit of the models (p <0.001). The mixed-
effects models, significant predictors and unstandardized
β coefficients with 95 % CI are presented in Tables 3 and
4. Older participants and those with more preserved IADL
capacity at baseline exhibited a more favourable longitu-
dinal cognitive outcome. A lower level of education and a
higher mean dose of ChEI during the study (irrespective
of drug agent) were independent predictors of better cog-
nitive ability as assessed by the ADAS-cog score in indi-
viduals with moderate AD. In the mixed-effects models,
living with a family member implied a mean reduction
of almost 3 points on ADAS-cog, and the presence of
NSAIDs/acetylsalicylic acid therapy implied a decrease
a
b
Fig. 3 Time to end-points. a Kaplan–Meier graph for the distribution of time from the start of ChEI therapy (approximately time of AD diagnosis)
to nursing home placement for the SATS group with mild vs. moderate AD. A log–rank test found a longer time to institutionalization for patients
with mild AD (p <0.001). b Kaplan–Meier graph for the distribution of time from the start of ChEI therapy to death according to stage of AD. A log-rank
test showed a shorter life expectancy for the patients with moderate AD (p <0.001). AD Alzheimer’s disease
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Completion rate (%) 95.1 87.1 74.6 58.9 48.8 33.4 27.2
MMSE scorea 18.2 (17.7, 18.6) 17.4 (16.8, 18.0) 15.8 (15.1, 16.4) 14.7 (13.8, 15.5) 13.9 (12.9, 14.9) 13.7 (12.5, 14.9) 12.8 (11.5, 14.1)
ADAS-cog score (0–70)a 28.8 (27.5, 30.2) 32.3 (30.6, 34.0) 35.0 (32.8, 37.1) 35.9 (33.3, 38.5) 36.4 (33.2, 39.5) 39.4 (35.7, 43.1)
IADL scorea 20.6 (20.0, 21.2) 22.3 (21.6, 22.9) 23.4 (22.6, 24.1) 24.3 (23.6, 25.0) 25.1 (24.3, 25.8) 26.2 (25.5, 27.0)
PSMS scorea 9.1 (8.6, 9.5) 9.8 (9.3, 10.3) 10.5 (9.9, 11.2) 10.8 (10.2, 11.4) 11.6 (10.8, 12.4) 12.6 (11.6, 13.6)
MMSE score, change from baselinea 1.77 (1.40, 2.14) 1.01 (0.52, 1.50) −0.60 (−1.18, −0.02) −1.79 (−2.58, −1.01) −2.82 (−3.73, −1.92) −3.20 (−4.29, −2.11) −4.03 (−5.22, −2.83)
ADAS-cog score (0–70), change from baselinea −0.14 (−1.19, 0.90) −3.85 (−5.13, −2.57) −6.56 (−8.26, −4.86) −8.18 (−10.14, −6.23) −9.52 (−11.98, −7.06) −13.22 (−16.16, −10.28)
IADL score, change from baselinea −1.48 (−1.89, −1.07) −3.17 (−3.66, −2.67) −4.09 (−4.73, −3.46) −5.31 (−6.09, −4.52) −6.19 (−7.23, −5.15) −7.50 (−8.71, −6.30)
PSMS score, change from baselinea −0.81 (−1.11, −0.51) −1.74 (−2.13, −1.36) −2.48 (−3.02, −1.94) −2.99 (−3.53, −2.45) −3.79 (−4.55, −3.04) −4.85 (−5.83, −3.88)
MMSE score, improved/unchanged patients (%) 74.5 66.4 51.5 45.2 32.8 36.7 28.9
ADAS-cog score (0–70), improved/unchanged
patients (%)
53.4 37.6 29.9 23.6 16.9 10.9
IADL score, improved/unchanged patients (%) 46.0 23.3 17.2 14.7 9.2 8.1
PSMS score, improved/unchanged patients (%) 62.4 45.5 34.9 23.3 21.8 17.6
For clarity, clinical improvements for all scales have been tabulated as positive changes from the start of ChEI therapy (baseline)
aMean (95 % confidence interval)

















of more than 2 points on the ADAS-cog outcome.
Usage of antipsychotics estimated an average score 2
points lower as measured by the MMSE scale. The
interaction effects of these variables with time were not
significant; that is, no additional increase in cognitive
impairment associated with the aforementioned variables
was detected during the 3-year study. Less functional
progression was related to better cognitive performance at
baseline and a higher mean ChEI dose.
Non-linear regression models for calculation of the
predicted MMSE, ADAS-cog, IADL or PSMS score for a
group of ChEI-treated patients with moderate AD, based
on the respective baseline score, are provided. These
equations are intended to predict the scores at subsequent
evaluations over a 3-year period. The models explained a
substantial degree of variance in the data set – that is, they
demonstrated a good fit: MMSE, R2 = 0.341, R = 0.584,
p <0.001; ADAS-cog, R2 = 0.466, R = 0.682, p <0.001; IADL,
R2 = 0.562, R = 0.750, p <0.001; and PSMS, R2 = 0.394,
R = 0.628, p <0.001. These non-linear regression model
equations are as follows:
Predicted MMSE score,
Y^ ¼ 14:9503− 0:2806 tð Þ− 0:7801 xið Þ
þ 0:0027 t2 þ 0:0613 xi2
 
Predicted ADAS-cog score,
Y^ ¼ 5:4994þ 0:1014 tð Þ þ 0:7152 xið Þ
þ 0:0120 txið Þ
Predicted IADL score,
Y^ ¼ 1:8953þ 0:5558 tð Þ
þ 0:9243 xið Þ− 0:0191 txið Þ
Predicted PSMS score,
Y^ ¼ −0:2714þ 0:2239 tð Þ
þ 1:0363 xið Þ− 0:0121 txið Þ
where t is the time in months between the baseline
score and the actual visit, and xi is the baseline MMSE
(ADAS-cog, IADL or PSMS) score.
Table 3 Factors affecting the long-term outcome with MMSE or ADAS-cog score as dependent variables
MMSE ADAS-cog
Significant predictors in final mixed modelsa β 95 % CI p β 95 % CI p
Percentage of variance accounted for, all fixed terms 38.5 %, p <0.001 47.8 %, p <0.001
Fixed terms
Intercept −0.936 −6.009, 4.137 0.717 21.058 8.622, 33.493 0.001
Time in months from baseline −0.887 −1.264, −0.509 <0.001 −0.215 −0.651, 0.221 0.333
Baseline assessment score 0.937 0.760, 1.114 <0.001 0.636 0.508, 0.765 <0.001
Time in months × baseline assessment score 0.016 0.002, 0.030 0.030 0.015 0.005, 0.025 0.003
Background variables
Solitary living (no = 0, yes = 1) ns 2.882 0.887, 4.877 0.005
NSAIDs/acetylsalicylic acid (no = 0, yes = 1) ns −2.368 −4.353, −0.383 0.020
Antipsychotics (no = 0, yes = 1) −1.985 −3.346, −0.625 0.004 ns
Education (years) ns −0.374 −0.865, 0.118 0.136
Time in months × education (years) ns 0.048 0.008, 0.089 0.020
Age at first assessment (years) 0.057 0.006, 0.109 0.030 −0.160 −0.288, −0.033 0.014
Time in months × age 0.005 0.001, 0.009 0.016 ns
IADL score at baseline −0.078 −0.156, −0.001 0.048 0.241 0.043, 0.439 0.017
ChEI doseb ns −0.057 −0.105, −0.010 0.018
Random terms (variance)
Intercept 4.671 3.445, 6.334 <0.001 11.382 5.851, 22.143 0.003
Time in months 0.029 0.021, 0.040 <0.001 0.174 0.128, 0.237 <0.001
Sex, apolipoprotein E genotype, age at onset, Physical Self-Maintenance Scale score at baseline, number of medications and the other specific concomitant medications
used at baseline, as well as the variable comparing the ChEI agents, were not significant predictors in the models. β values were unstandardized and are expressed per
1 unit increase for continuous variables and for the condition present in dichotomous variables
aBaseline assessment score = MMSE or ADAS-cog, respectively
bMean percentage of the maximum recommended dose; that is, 10 mg for donepezil, 12 mg for rivastigmine, and 24 mg for galantamine
ADAS-cog Alzheimer’s Disease Assessment Scale—cognitive subscale, ChEI cholinesterase inhibitors, CI confidence interval, IADL Instrumental Activities of Daily
Living, MMSE Mini-Mental State Examination, ns not significant, NSAID non-steroidal anti-inflammatory drug
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Discussion
In this study conducted in routine clinical practice, vary-
ing 3-year outcomes between participants in the two
different stages of AD were demonstrated depending on
the measures used. No significant difference was found
between the MMSE and IADL scores, whereas the de-
terioration using ADAS-cog and basic ADL scales was
faster in the group with moderate AD. Nursing home
placement during the study was less frequent for the
patients with mild AD, but the proportion of deceased
individuals between the two stages did not differ after
3 years. Using mixed-effects models, risk factors for
worse cognitive long-term outcome in moderate AD
were antipsychotic medications, no usage of NSAIDs/
acetylsalicylic acid, living alone, younger age, more years
of education and lower IADL capacity. A higher mean
ChEI dose was associated with slower cognitive and
functional decline. Prediction models with the variance
explained to a larger extent were also presented for the
moderate cohort.
There has been increased interest in disease progres-
sion and response to therapies in various stages of AD
after the solanezumab phase 2 [9] and Souvenaid [8] tri-
als that reported small, but significant, positive outcomes
for participants with mild AD. The solanezumab phase 3
trials [10] showed no placebo-treatment differences in
cognition; however, the ‘placebo’ (the majority of pa-
tients were treated with ChEIs and/or memantine) group
with mild AD deteriorated, on average, 5.1 points on the
ADAS-cog scale and 2.4 points in MMSE score after
18 months. The corresponding decline in the SATS was
2.6 points and 1.3 points [2]. The mean deterioration for
the moderate ‘placebo’ group in the 18-month solanezu-
mab trial was 10.9 points on the ADAS-cog scale and
5.8 points in MMSE score, whereas the declines in SATS
participants were 6.6 points and 1.8 points, respectively.
A 6-month randomized controlled trial of idalopirdine
in patients with moderate AD found a mean deterioration
of 1.38 points on the ADAS-cog scale in the donepezil-
treated ‘placebo’ group [11], while the current study
demonstrated an average deterioration of 0.14 points after
6 months. The participants in both the solanezumab and
idalopirdine trials were on stable treatment with ChEIs
and/or memantine before their inclusion in the trials [10,
11]. The slower rate of cognitive impairment over time re-
ported in the SATS might reflect a positive response to
continuous ChEI therapy in the first months after initi-
ation; therefore, it may be important to consider the point
when treatment with ChEIs was started when comparing
measures of disease progression between studies.
The cognitive rates of change over time between the
patients with mild vs. moderate AD in the present study
differed appreciably, depending on the chosen test
instrument—MMSE or ADAS-cog, which are commonly
used during these stages of AD. The selected assess-
ment scale can affect the detected profile and rate of
Table 4 Factors affecting the long-term outcome with IADL or PSMS score as dependent variables
IADL PSMS
Significant predictors in final mixed modelsa β 95 % CI p β 95 % CI p
Percentage of variance accounted for, all fixed terms 56.0 %, p <0.001 39.9 %, p <0.001
Fixed terms
Intercept 2.375 −3.349, 8.099 0.414 4.844 2.154, 7.534 <0.001
Time in months from baseline 0.515 0.407, 0.623 <0.001 0.188 0.162, 0.213 <0.001
Baseline assessment score 1.431 0.926, 1.936 <0.001 0.900 0.789, 1.011 <0.001
Baseline assessment score2 −0.016 −0.029, −0.003 0.019 ns
Time in months × baseline assessment score −0.013 −0.017, −0.008 <0.001 ns
Time in months2 × baseline assessment score −0.0001 −0.0002, −0.00002 0.010 ns
Background variables
MMSE score at baseline −0.195 −0.374, −0.016 0.033 −0.203 −0.339, −0.067 0.004
ChEI doseb −0.025 −0.048, −0.002 0.037 −0.019 −0.035, −0.003 0.021
Random terms (variance)
Intercept 5.089 3.832, 6.757 <0.001 1.762 1.048, 2.963 <0.001
Time in months 0.008 0.005, 0.012 <0.001 0.017 0.013, 0.024 <0.001
Sex, apolipoprotein E genotype, solitary living, age at onset, age at baseline, years of education, number of medications and specific concomitant medications used at
baseline, as well as the variable comparing the ChEI agents, were not significant predictors in the models. β values were unstandardized and are expressed per 1 unit
increase for continuous variables and for the condition present in dichotomous variables
aBaseline assessment score = IADL or PSMS, respectively
bMean percentage of the maximum recommended dose; that is, 10 mg for donepezil, 12 mg for rivastigmine and 24 mg for galantamine
ChEI cholinesterase inhibitors, CI confidence interval, IADL Instrumental Activities of Daily Living, MMSE Mini-Mental State Examination, ns not significant, PSMS
Physical Self-Maintenance Scale
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deterioration [21]. For example, a ceiling effect (the scale
is less sensitive in the detection of actual changes during
the very mild stage) and a floor effect (inability to evaluate
severely impaired persons adequately) might affect the
apparent trajectories. Moreover, a change in the score on
a certain test is expected to be greater at the level of func-
tion, at which the scale measures the individual’s capaci-
ties most accurately [22]. Our findings indicate that the
items in the more complex ADAS-cog scale are better
adapted to measure the cognitive performance of the co-
hort with moderate AD, and that the MMSE seems to be
less sensitive in describing the rate of change in cognition
for participants with mild or moderate AD. This calls for
the use of other scales that are more sensitive to changes
in the progression of the disease (e.g. ADAS-cog). In clin-
ical practice, the MMSE test is simpler to administer than
the ADAS-cog; however, the latter is better when it comes
to measuring change from a scientific point of view. The
higher percentage of the explained variance observed for
the ADAS-cog score compared with MMSE score (48 %
vs. 38 %) in our mixed-effects models strengthens this
observation. Knowledge of the expected long-term pro-
gression rate in various scales and stages of AD is clinic-
ally important for patient prognosis and anticipated care
needs (i.e. whether the individual is declining at a rapid or
slow rate) and for the assessment of the effectiveness of
new therapies (e.g. calculation of sample sizes).
Surprisingly, no significant difference in the rate of IADL
deterioration was detected between participants with mild
and moderate AD after 3 years in this study. Our previous
study of mild AD found that 45–65 % of the patients
needed assistance with IADL tasks at baseline [2]. The
current study showed that nursing home placement was
less frequent among individuals with mild AD. However,
the time to institutionalization for those who were admitted
and the proportion of deaths over the 3-year study did not
differ between the disease stages. A recent review reported
that IADL impairment occurred early at a stage of mild cog-
nitive impairment [23]. These observations stress the need
for functional evaluations during the early phases of cogni-
tive decline. Information about the patient’s IADL abilities
is important knowledge for family members, clinicians and
community-based services, for example, to assess safety is-
sues (driving, management of own finances and medica-
tion intake) and to provide an adequate amount of formal
care to postpone nursing home placement.
The significant predictors of progression in the moder-
ate stage of AD varied somewhat between the MMSE
and ADAS-cog scales in the present study. A higher
level of education significantly precipitated the cognitive
impairment measured by the ADAS-cog scale, but not
the MMSE score, over time. Individuals with more years
of education are expected to have a higher premorbid
cognitive status. Hence, they might have a relatively
larger burden of AD pathology and a more advanced
level of the disease when dementia is clinically manifest
[24]. This is one explanation for the influence of educa-
tion level on the more demanding ADAS-cog scale in
our group of participants with moderate AD. More years
of education in patients with mild or mild-to-moderate
AD have been related to faster cognitive deterioration
using both MMSE and ADAS-cog scales [2, 7, 25], indi-
cating a greater neurodegeneration at the time of AD
diagnosis and delayed initiation of anti-dementia therapy
compared with those with a lower level of education.
In the current analyses of moderate AD, the presence
of NSAIDs/acetylsalicylic acid medications was a pro-
tective factor for a better longitudinal outcome in cogni-
tion (ADAS-cog score). We also found this protective
factor in our entire SATS cohort with mild to moderate
AD [7], but not in participants exclusively in the mild
stage of AD [2]. Neuroinflammation has been suggested
to participate in the pathogenetic cascades of AD, and a
recent study from our group demonstrated that cerebral
inflammation was an independent predictor of earlier
death in AD [26]. The findings lead to the hypothesis
that anti-inflammatory drugs could act as possible pre-
ventive or therapeutic approaches. A recent meta-analysis
of observational studies shows that use of NSAIDs and
aspirin, particularly over longer periods, could significantly
prevent the occurrence of AD [27]. However, a review of
randomized trials found no effect of NSAID therapy on
cognitive decline compared with placebo in patients with
mild to moderate AD; however, none of the included stud-
ies was longer than 12 months [28]. Nor was any benefi-
cial effect observed in an 18-month trial of tarenflurbil in
mild AD exclusively [13]. An explanation for these nega-
tive findings is that the follow-up period was not suffi-
ciently long enough for a therapeutic effect to emerge in
comparison with the 3-year perspective of the SATS. In
addition, individuals with more advanced disease and
neuroinflammation might have additional benefit from
longer-term treatment with anti-inflammatory drugs and
their potential for slowing AD progression.
In this study, the use of antipsychotics and solitary
living were found to be independent risk factors for a
more rapid cognitive deterioration in moderate AD;
however, these predictors were not found to be signifi-
cant in our study of SATS participants with mild AD [2].
Hallucinations and delusions are common in the more
advanced stages of AD; thus, these symptoms and anti-
psychotic medication might not affect the outcomes in
milder forms of the disease. Psychotic symptoms and the
use of antipsychotics have shown a relationship with a
faster rate of cognitive impairment and worse prognosis
in earlier studies of patients with AD [29, 30], which
supports our findings. Living alone implied an additional
3-point mean reduction of the outcome in ADAS-cog
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score in individuals with moderate AD in the present
study, but this finding was not observed in the group
with mild AD. However, participants with mild AD who
lived alone exhibited more rapid worsening in IADL
compared with those living with family [2]. In mild de-
mentia, IADL deficits were more strongly associated
with impairment in performance than in initiative [31];
thus, individuals with mild AD living alone could be
dependent on support to maintain their performance of
daily activities. Possible effects of solitary living, such as
loneliness, social isolation and apathy, might also nega-
tively affect disease progression. Apathy is more preva-
lent in the moderate/severe stages of dementia and has
been reported as a predictor of faster cognitive decline
[32]. This symptom might have a larger influence on the
speed of cognitive impairment in the moderate stage,
which might explain our findings. Furthermore, higher
cognitive status in community-living elderly people is
related to increased social support; that is, marital status
and perceived positive support from friends [33]. We
recently found that patients with mild AD living alone
received an equal amount of home-help services as those
with moderate AD [34]. These observations emphasize
the risk of isolation and lack of mental stimulation
among the vulnerable solitary-living care recipients with
more advanced AD.
In this study of moderate AD, a higher mean dose of
ChEI irrespective of the agent demonstrated a more
favourable long-term outcome in both cognitive and
functional capacities. Studies including participants in
the mild and mild-to-moderate stages of AD from our
group and others have previously reported this associ-
ation [2, 7, 35, 36], which is considered essential know-
ledge for clinicians. Patients with more advanced AD
have exhibited a better short-term response to ChEI
therapy than those with milder disease in randomized
trials and observational studies [4, 6]. A larger reversible
cholinergic deficit in the more severe stages of AD
could be a potential explanation [37]. The current
longitudinal study shows the clinical importance of using
optimal doses of ChEIs when treating individuals with
moderate AD.
The strengths of the observational, prospective SATS
are the large sample and well-structured semi-annual
assessments of different aspects of AD progression over
3 years after the start of ChEI therapy. ‘Real-world’ AD
outpatients with concomitant disorders and medications
from 14 memory clinics across Sweden were enrolled.
All participants were continuously treated with ChEIs
during the study, and compliance in the SATS was high,
which was investigated via an analysis of the level of the
plasma concentration of the drug [14]. The Swedish
health care system and its community-based services are
publicly funded for all residents of Sweden [38], which
assumes a representative selection of patients with AD
and that the services used reflect the individuals’ actual
needs for formal help, irrespective of socio-economic
status. Like other longer-term naturalistic studies of AD,
the limitations are that the SATS was not placebo con-
trolled because of ethical concerns or was not random-
ized with respect to ChEI drug agent. Specialists in
dementia disorders decided on the type of ChEI and
dose for each participant, in agreement with the stan-
dards used in a routine clinical setting. Individuals who
discontinued the study might have a worse prognosis
than the completers, suggesting that the drop-outs had
less benefit from ChEI treatment.
To our knowledge, no studies have previously compared
the longitudinal cognitive and functional outcomes be-
tween patients with mild and moderate stages of AD;
therefore, additional studies are warranted to confirm our
findings. The potential effect of ChEI in various disease
stages and possible risk factors that might alter the prog-
nosis, such as co-morbidity and concomitant medications,
need further investigation. This knowledge is essential to
assess the effectiveness of and provide realistic expecta-
tions for new potentially disease-modifying AD therapies
directed at different stages of AD. Baseline-dependent
statistical models with the variance explained to a large
extent were provided in the present study and could be
used to predict the mean cognitive and functional out-
comes for a ChEI-treated cohort with moderate AD in
forthcoming studies of, for example, long-term combin-
ation therapy.
Conclusions
A comparison of various aspects of disease progression
between mild vs. moderate AD was reported in this
observational 3-year study. The cognitive decline was
significantly faster among the participants with moderate
AD using the ADAS-cog scale, but not the MMSE test,
indicating that the measure was dependent on the scales
used. Deterioration on the IADL scale was similar be-
tween the different disease stages examined; however,
the rate of basic ADL impairment was more pronounced
in the group with moderate AD. This finding has im-
portant clinical implications, underlining the importance
of functional assessments in the early stages of AD to
avoid safety issues (e.g. driving and financial capacity)
and to offer these impaired individuals the necessary
formal care. Use of NSAIDs/acetylsalicylic acid was a
protective factor for better cognitive outcome in moder-
ate AD, suggesting that patients with greater neurode-
generation and cerebral inflammation have additional
advantages of longer-term treatment with these drugs.
Solitary living was a risk factor for more rapid cognitive
progression in the moderate cohort, underlining the risk
of apathy and social isolation among individuals with
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more advanced AD. A higher mean dose of ChEI was
independently associated with slower cognitive and func-
tional decline among the group of participants with
moderate AD, stressing the importance of also optimiz-
ing the dose for patients in this group. Prediction models
designed for the cohort with moderate AD are presented
for the first time in this study; these models might be a
useful tool with which to estimate the mean cognitive
and functional outcomes that may be expected using
ChEI monotherapy over extended times.
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